AGE-RELATED MACULAR DEGENERATION

CASE 54-13

QUESTION 1: E.A., a 77-year-old woman, informs you she read information from the Internet and she thinks

her symptoms of blurred vision and the need for a bright light to read are consistent with age-related macular

degeneration. She asks which of the available medicines would be best for her.

Age-related macular degeneration is the leading cause of blindness in Americans

of European descent who are 55 years of age and older.

170 There are two forms of

macular degeneration, wet and dry. The dry form, affecting about 85% of patients,

develops as a result of the breakdown of light-sensitive cells in the macula.

171 The

most common symptom associated with dry macular degeneration is blurred vision.

In this situation, details (e.g., faces, words in a book) are seen less clearly. Wet

macular degeneration occurs in 15% of patients and is the more serious form,

responsible for the most cases of vision loss. One of the first symptoms of wet

macular degeneration is the appearance of straight lines as wavy. Wet macular

degeneration is associated with abnormal growth of blood vessels behind the retina,

known as choroidal neovascularization. Vascular endothelial growth factor (VEGF)

is associated with the pathogenesis of choroidal

p. 1168

p. 1169

neovascularization. VEGF may stimulate neovascularization by influencing

endothelial cell proliferation, vascular permeability, and ocular inflammation.

172 The

correlation between VEGF and wet age-related macular degeneration has led to

interest in VEGF inhibitors (pegaptanib, bevacizumab, ranibizumab) as treatment

agents.

PEGAPTANIB

Pegaptanib inhibits angiogenesis, decreases permeability of the vascular bed, and

decreases inflammation. The efficacy of pegaptanib has been evaluated in two

concurrent, prospective, randomized, double-blind trials involving 1,208 patients. A

total of 1,190 patients received at least one study treatment, with four subjects being

excluded from the efficacy analysis owing to insufficient assessment of visual acuity

at baseline. A combined analysis of 1,186 patients at week 54 showed a statistically

significant reduction in vision loss associated with pegaptanib, realized as early as

week 6 and continued through week 54.

173 The FDA-approved dose of pegaptanib

(0.3 mg intravenously every 6 weeks) is no less effective than 1- or 3-mg doses, and

the most serious injection-related adverse events were endophthalmitis (12 patients),

traumatic injury to the lens (five patients), and retinal detachment (six patients).

173

Patients should be monitored for elevations in IOP after injection; increases in IOP

have been seen within 30 minutes of injection and should be monitored within 2 to 7

days after the injection.

BEVACIZUMAB

Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody

approved for intravenous use for first- or second-line treatment of metastatic

colorectal cancer. This product has been used off-label via the intravenous and

intravitreal routes for the treatment of neovascular ocular disorders in more than

3,500 patients.

172

Intravenous bevacizumab 5 mg/kg was administered every 2 weeks

for two or three infusions in 18 patients for whom 12- and 24-week results on

subfoveal choroidal neovascularization were published separately. Therapy was

associated with improved visual acuity. No serious ocular or systemic adverse

effects were noted, although a statistically significant increase in blood pressure was

noted at week 3. Nineteen published, uncontrolled case series studies have evaluated

the use of intravitreal bevacizumab for the treatment of wet macular degeneration as

well as other conditions associated with neovascularization. The most common

intravitreal dose was 1.25 mg, usually administered every 4 to 6 weeks. Doses could

be repeated if signs of progression occurred. The longest period of study for

intravitreal use was 1 year. The majority of patients in these open-label trials were

followed up for 3 months. Mean visual acuity improved, and no serious ocular

effects were noted.

RANIBIZUMAB

Ranibizumab is a Fab fragment of bevacizumab approved in June 2006 for the

intravitreal treatment of wet macular degeneration. Ranibizumab is approximately

one-third the size of bevacizumab. Its size may facilitate retinal penetration after

intravitreal injection. Ranibizumab has a shorter-systemic half-life and higher VEGF

binding affinity than bevacizumab, but bevacizumab has two binding sites per

molecule versus one for ranibizumab. The clinical relevance of these

pharmacokinetic and pharmacodynamic differences is not known.

172 The

recommended dosage of ranibizumab is 0.5 mg via the intravitreal route administered

every 4 weeks. This treatment has been associated with maintenance or improvement

of vision for 12 to 24 months.

173 The primary ocular side effects associated with

ranibizumab administration include conjunctival hemorrhage, eye pain, and increased

IOP.

Bevacizumab is significantly less expensive than ranibizumab. Similar efficacy

associated with lower cost may lead to increased use for neovascular age-related

macular degeneration. The National Eye Institute has initiated the Comparisons of

Age-Related Macular Degeneration Treatments Trials, a multicenter, randomized

clinical trial of ranibizumab and bevacizumab in the treatment of neovascular agerelated macular degeneration.

174

AFLIBERCEPT

In September 2012, aflibercept became the second VEGF inhibitor approved for

treatment of macular edema secondary to choroidal vein retinal occlusion (CRVO).

Preliminary results from the ongoing COPERNICUS and GALILEO trials proved the

efficacy of this medication in treating macular edema secondary to CRVO. Of the

combined 358 patients studied in COPERNICUS and GALILEO, 56% and 60%,

respectively, of the patients receiving aflibercept 2 mg monthly achieved at least a

15-letter improvement in best-corrected visual acuity (BCVA) from baseline over 6

months compared with just 12% and 22% in the control group (p < 0.01 for both).

Additionally, in COPERNICUS and GALILEO, patients achieved a 21.3- and 14.7-

letter improvement, respectively, in BCVA compared with placebo ( p < 0.01 for

both).

175

While efficacy and safety appear similar to other anti-VEGF treatments, the higher

potency, binding affinity, and duration of action make aflibercept an appealing new

option.

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key reference and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Riordan-Eva P, Whitcher JP, eds. Vaughan and Ashbury’s General Ophthalmology . 18th ed. New York, NY:

McGraw-Hill Professional; 2011. (1)

Key Websites

American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco,

CA: American Academy of Ophthalmology; 2010. http://www.aao.org/ppp. Accessed June 2015. (5)

COMPLETE REFERENCES CHAPTER 54 EYE DISORDERS

Riordan-Eva P, Whitcher JP, eds. Vaughan and Ashbury’s General Ophthalmology . 18th ed. New York, NY:

McGraw-Hill Professional; 20011.

Tham YC et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic

review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.

Glaucoma Facts and Stats. Glaucoma Research Foundation. May 5, 2015.

http://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php. Accessed December 2015.

Gordon MO et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary

open-angle glaucoma. Arch Ophthalmol. 2002;120:714.

American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco,

CA: American Academy of Ophthalmology, 2010. http://www.aao.org/ppp. Accessed June 2015.

Rakofsky SI et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol

treatment. Ophthalmology. 1989;96:8.

Berson FG et al. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure.

Arch Ophthalmol. 1985;103:379.

Battershill PE, Sorkin EM. Ocular metipranolol: a preliminary review of its pharmacodynamic and pharmacokinetic

properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1988;36:601.

Mills KB, Wright G. A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in openangle glaucoma: a pilot study. Br J Ophthalmol. 1986;70:39.

Krieglstein GK et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort.

Br J Ophthalmol. 1987;71:250.

Scoville B et al. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol.

1988;105:150.

Stewart WC et al. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma.

Graefes Arch Clin Exp Ophthalmol. 1991;229:258.

Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy

volunteers. Br J Ophthalmol. 1988;72:101.

Levy NS et al. A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy.

Glaucoma. 1985;7:54.

Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol. 1977;95:605.

Kwitko GM et al. Bilateral effects of long-term monocular timolol therapy. Am J Ophthalmol. 1987;104:591.

Britman NA. Cardiac effects of topical timolol. N EnglJ Med. 1979;300:566.

Kim JW, Smith PH. Timolol-induced bradycardia. Anesth Analg. 1980;59:301.

McMahon CD et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol. 1979;88:736.

Jones FL Jr, Ekberg NL. Exacerbation of asthma by timolol. N EnglJ Med. 1979;301:270.

Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol. 1979;88:739.

Draeger J, Winter R. The local anaesthetic action of metipranolol versus timolol in patients with healthy eyes. In:

Merte HJ, ed. Metipranolol Pharmacology of Beta-Blocking Agents and Use of Metipranolol in Ophthalmology.

Contributions to the First Metipranolol Symposium, Berlin 1983. New York, NY: Springer-Verlag Wien;

1983:76.

Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519.

Zimmerman TJ et al. Side effects of timolol. Surv Ophthalmol. 1983;28(Suppl):243.

Rozier A et al. Gelrite: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on

bioavailability of timolol. Int J Pharm. 1989;57:163.

Shedden AH et al. Multiclinic, double-masked study of 0.5% Timoptic-XE once daily versus 0.5% Timoptic twice

daily [abstract]. Ophthalmology. 1993;100(Suppl):111.

Berson FG et al. Levobunolol: a β-adrenoreceptor antagonist effective in the long-term treatment of glaucoma.

The Levobunolol Study Group. Ophthalmology. 1985;92:1271.

Akingbehin T et al. Metipranolol-induced adverse reactions: I. The rechallenge study. Eye (Lond). 1992;6(Pt

3):277.

Akingbehin T, Villada JR. Metipranolol-induced adverse reactions: II. Loss of intraocular pressure control. Eye

(Lond). 1992;6(Pt 3):280.

Bacon PJ et al. Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers. Br J Clin

Pharmacol. 1989;27:1.

Berry DP Jr et al. Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol.

1984;102:42.

Stewart RH et al. Betaxolol vs. timolol: a six-month double-blind comparison. Arch Ophthalmol. 1986;104:46.

Allen RC et al. A double-masked comparison of betaxolol vs. timolol in the treatment of open-angle glaucoma.

Am J Ophthalmol. 1986;101:535.

Zioptan [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2012.

Alexander CL et al. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother.

2002;36:504.

Xalatan [prescribing information]. New York, NY: Pfizer, Pharmacia and Upjohn Company; 2009.

Camras CB et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from

timolol. United States Latanoprost Study Group. Am J Ophthalmol. 1998;126:390.

Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in

combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle

glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8:24.

Simmons ST et al. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and

ocular hypertension patients uncontrolled on j-blockers: tolerance and peak intraocular pressure lowering.

Ophthalmology. 2002;109:307.

Hoyng PF et al. The additive intraocular pressure-lowering effects of latanoprost in combined therapy with other

ocular hypotensive agents. Surv Ophthalmol. 1997;41(Suppl 2):S93.

Kimal Arici M et al. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

Int Ophthalmol. 1998;22:37.

Smith SL et al. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or

adjunctive therapy. J Ocul Pharmacol Ther. 1999;15:29.

Netland PA et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or

ocular hypertension. Am J Ophthalmol. 2001;132:472.

Goldberg I et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in

patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414.

Travatan [prescribing information]. Fort Worth, TX: Alcon Pharmaceuticals; 2004.

Sherwood M et al. Six-month comparison of bimatoprost once-daily and twice daily with timolol twice daily in

patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361.

Noecker RS et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of

bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55.

Lumigan [prescribing information]. Irvine, CA: Allergan; 2010.

Latisse (Bimatoprost Ophthalmic Solution) [prescribing information]. Irvine, CA: Allergan; 2009.

Uusitalo H et al. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle

glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta

Ophthalmol. 2010;88:12–19.

Chabi A et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in

patients with open-angle glaucoma or ocular hypertension. Am J Ophthamol. 2012;153:1187–1196.

Ergorov E et al. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular

pressure in patients with glaucoma. Eur J Ophthamol. 2009;19:214–222.

Januleviciene I et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular

pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–109.

Uusitalo H et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma

medication. Acta Ophthamol. 2010;88:329–336.

Toris CB et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol.

1995;113:1514.

Alphagan P [prescribing information]. Irvine, CA: Allergan; 2008.

Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared

with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000;22:103.

Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in

subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(Suppl

1):S39.

DuBiner HB et al. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with

open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallelgroup trial. Clin Ther. 2001;23:1969.

Sall KN et al. Dorzolamide/timolol combination verses concomitant administration of brimonidine and timolol:six-

month comparison of efficacy and tolerability. Ophthalmology. 2003;110:615.

Strahlman E et al. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and

betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113:1009.

Wayman L et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch

Ophthalmol. 1997;115:1368.

Simbrinza [prescribing information]. Fort Worth, Texas: Alcon; 2014.

Azopt [prescribing information]. Fort Worth, TX: Alcon Laboratories; 2008.

Trusopt [prescribing information]. Whitehouse Station, PA: Merck & Co; 2009.

Rosenberg LF et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular

pressure and aqueous humor formation. Ophthalmology. 1998;105:88.

Harris LS. Dose-response analysis of echothiophate iodide. Arch Ophthalmol. 1971;86:503.

Yüksel N et al. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle

glaucoma. Ophthalmologica. 1999;213:228.

Sorensen SJ, Abel SR. Comparison of the ocular β-blockers. Ann Pharmacother. 1996;30:43.

Berson FG, Epstein DL. Separate and combined effects of timolol maleate and acetazolamide in open-angle

glaucoma. Am J Ophthalmol. 1981;92:788.

Strahlman ER et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with

elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology. 1996;103:1283.

thoe Schwartzenberg GW, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with

glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology. 1999;106:1616.

Orzalesi N et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on

circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol.

2003;121:453.

Van Buskirk EM et al. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol. 1986;101:531.

Zimmerman TJ et al. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J

Ophthalmol. 1992;114:1.

Ellis PP et al. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye.

J Pharm Sci. 1992;81:219.

Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol.

1993;37:435.

Zambarakji HJ et al. An unusualside effect of dorzolamide. Eye (Lond). 1997;11(Pt 3):418.

Galin MA et al. Ophthalmological use of osmotic therapy. Am J Ophthalmol. 1966;62:629.

Drance SM. Effect of oral glycerol on intraocular pressure in normal and glaucomatous eyes. Arch Ophthalmol.

1964;72:491.

Becker B et al. Isosorbide: an oral hyperosmotic agent. Arch Ophthalmol. 1967;78:147.

Adams RE et al. Ocular hypotensive effect of intravenously administered mannitol; a preliminary report. Arch

Ophthalmol. 1963;69:55.

D’Alena P, Ferguson W. Adverse effects after glycerol orally and mannitol parenterally. Arch Ophthalmol.

1966;75:201.

Spaeth GL et al. Anaphylactic reaction to mannitol. Arch Ophthalmol. 1967;78:583.

Fraunfelder FT, Fraunfelder FW. Drug-Induced Ocular Side Effects. Boston, MA: Butterworth Heinemann;

2001.

Grant WM. Toxicology of the Eye. 2nd ed. Springfield, IL: Charles C. Thomas; 1974.

D’Amico DJ et al. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981;99:257.

Kaplan LJ, Cappaert WE. Amiodarone keratopathy: correlation to dosage and duration. Arch Ophthalmol.

1982;100:601.

Risperidone (Risperdal) [prescribing information]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc;

1997.

Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications. Drugs. 2007;67:75.

Nicastro NJ. Visual disturbances associated with over-the-counter ibuprofen in three patients. Ann Ophthalmol.

1989;21:447.

Hamill MB et al. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure

glaucoma. Ann Ophthalmol. 1983;15:1011.

Bar S et al. Presenile cataracts in phenytoin-treated epileptic patients. Arch Ophthalmol. 1983;101:422.

Marsch SCU, Schaefer HG. Problems with eye opening after propofol anesthesia. Anesth Analg. 1990;70:127.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

Cunningham M et al. Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry.

1990;147:947.

Fraunfelder FT, Meyer SM. Amantadine and corneal deposits. Am J Ophthalmol. 1990;110:96.

Flach A. Photosensitivity to sulfisoxazole ointment. Arch Ophthalmol. 1981;99:609.

Flach AJ et al. Photosensitivity to topically applied sulfisoxazole ointment: evidence for a phototoxic reaction.

Arch Ophthalmol. 1982;100:1286.

VFEND [prescribing information]. New York, NY: Pfizer Roerig Pharmaceuticals; 2003.

Laties AM et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human

lens after 48 weeks of treatment with lovastatin. Am J Cardiol. 1991;67:447.

Shingleton BJ et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol. 1981;100:1766.

Hopen G et al. Corneal toxicity with systemic cytarabine. Am J Ophthalmol. 1981;91:500.

Pitlik S et al. Transient retinal ischaemia induced by nifedipine. Br Med J (Clin Res Ed). 1983;287:1845.

Leibowitz HM et al. Comparative anti-inflammatory efficacy of topical corticosteroids with low glaucomainducing potential. Arch Ophthalmol. 1992;110:118.

Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The

demonstration of three levels of response. Invest Ophthalmol. 1965;4:187.

Franufelder FT, Meyer SM. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids.

Am J Ophthalmol. 1990;109:489.

Jick H, Brandt DE. Allopurinol and cataracts. Am J Ophthalmol. 1984;98:355.

Gleevec [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2010.

Friedman DI et al. Neuro-ophthalmic complications of interleukin 2 therapy. Arch Ophthalmol. 1991;109:1679.

Cialis [prescribing information]. Indianapolis, IN: Eli Lilly & Company; 2003.

Levitra [prescribing information]. West Haven, CT: Bayer Health Care; 2003.

Viagra [prescribing information]. New York, NY: Pfizer, Inc; October 2007.

Fraunfelder FT, Fraunfelder FW. Drug-related adverse effects of clinical importance to the ophthalmologist.

National Registry of Drug-Induced Ocular Side Effects. http://www.eyedrugregistry.com. Accessed

September 1, 2010.

Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract

Surg. 2005;31:664.

Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to

evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol.

1998;125:797.

Emadine [prescribing information]. Fort Worth, TX: Alcon Laboratories; 1999.

Zaditor [prescribing information]. Duluth, GA: CIBA Vision; 1999.

Yanni JM et al. Preclinical efficacy of emedastine, a potent selective histamine H1 antagonist for topical ocular

use. J Ocul Pharmacol. 1994;10:665.

Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management

with 0.1% olopatadine hydrochloride versus ketotifen fumarate. Acta Ophthalmol Scand Suppl. 2000;(230):52.

Spangler DL et al. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and

azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther.

2001;23:1272.

McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus

olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol.

2012;6:1731.

Ackerman S et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and

olopatadine 0.2% in the conjunctival allergy challenge model. J Asthma Allergy. 2013;6:43.

Caldwell DR et al. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal

keratoconjunctivitis. Am J Ophthalmol. 1992;113:632.

Fahy GT et al. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease.

A multicentre study. Eur J Ophthalmol. 1992;2:144.

Butrus S et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic

solution and nedocromil sodium 2% solution in the human conjunctival allergen challenge model. Clin Ther.

2000;22:1462.

Baum JL. Initial therapy of suspected microbial corneal ulcers: I. Broad antibiotic therapy based on prevalence

of organisms. Surv Ophthalmol. 1979;24:97.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

Jones DB. Initial therapy of suspected microbial corneal ulcers: II. Specific antibiotic therapy based on corneal

smears. Surv Ophthalmol. 1979;24:97.

Çaça I et al. Therapeutic effect of culture and antibiogram in bacterial corneal ulcers. Ann Opthalmol.

2005;37:191.

Leibowitz H et al. Bioavailability and effectiveness of topically administered corticosteroids. Trans Am Acad

Ophthalmol Otolaryngol. 1975;79:78.

Leibowitz HM, Kupferman A. Anti-inflammatory effectiveness in the cornea of topically administered

prednisolone. Invest Ophthalmol. 1974;13:757.

Kupferman A, Leibowitz HM. Therapeutic effectiveness of fluorometholone in inflammatory keratitis. Arch

Ophthalmol. 1975;93:1011.

Becker B, Ballin N. Glaucoma and corticosteroid provocative testing. Arch Ophthalmol. 1965;74:621.

Stewart RH et al. Ocular pressure response to fluorometholone acetate and dexamethasone phosphate. Curr

Eye Res. 1984;3:835.

Godel V et al. Systemic steroids and ocular fluid dynamics. II. Systemic versus topical steroids. Acta

Ophthalmol (Copenh). 1972;50:664.

Cantrill HL et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am

J Ophthalmol. 1975;79:1012.

Stewart RH, Kimbrough RL. Intraocular pressure response to topically administered fluorometholone. Arch

Ophthamol. 1979;97:2139.

Leibowitz HM et al. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to

corticosteroids. Arch Ophthalmol. 1996;114:933.

Dell SJ et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic

treatment of seasonal allergic conjunctivitis. International Dorzolamide Study Group. Am J Ophthalmol.

1997;123:791.

Kitazawa Y, Horie T. The prognosis of corticosteroid-responsive individuals. Arch Ophthalmol. 1981;99:819.

Oglesby RB et al. Cataracts in rheumatoid arthritis patients treated with corticosteroids: description and

differential diagnosis. Arch Ophthalmol. 1961;66:519.

Oglesby RB et al. Cataracts in patients with rheumatic diseases treated with corticosteroids: further

observations. Arch Ophthalmol. 1961;66:625.

Skalka HW, PrchalJT. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980;98:1773.

Yablonski MF et al. Cataracts induced by topical dexamethasone in diabetics. Arch Ophthalmol. 1978;96:474.

Sevel D et al. Lenticular complications of long-term steroid therapy in children with asthma and eczema. J

Allergy Clin Immunol. 1977;60:215.

Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol.

1978;85:447.

Brown MM et al. Lack of side effects from topically administered 10% phenylephrine eye drops: a controlled

study. Arch Ophthalmol. 1980;98:487.

Morton HG. Atropine intoxication: its manifestations in infants and children. J Pediatr. 1939;14:755.

Mark HH. Psychotogenic properties of cyclopentolate. JAMA. 1963;186:430.

Freund M, Merin S. Toxic effects of scopolamine eye drops. Am J Ophthalmol. 1970;70:637.

Hoefnagel D. Toxic effects of atropine and homatropine eye drops in children. N EnglJ Med. 1961;264:168.

WahlJW Systemic reaction to tropicamide. Arch Ophthalmol. 1969;82:320.

Abrams SM et al. Marrow aplasia following topical application of chloramphenicol eye ointment. Arch Intern

Med. 1980;140:576.